Pain Perception in Alzheimer's Disease
The purpose of this study is to determine response to pain in Alzheimer’s disease.We plan to study the effect of diffuse noxious inhibitory controls(counterirritation phenomenon)and the autonomic nervous system reaction(reflected by the heart rate) in Alzheimer’s disease. The study’s hypothesis is that pain perception and autonomic nervous system reaction are altered in Alzheimer’s disease.
Status: Recruiting (N/A). Started on June 1st, 2005.
Enrollment: 60 subjects
Study Type: Observational
Study Design:
- Screening
- Cross-Sectional
- Defined Population
- Prospective Study
Conditions:
Interventions:
- Behavioral: reaction to pain
Eligibility
Inclusion Criteria:
- Clinical diagnosis of Alzheimer’s disease Must be able to understand a simple pain scale
Exclusion Criteria:
Neuropathy Psychotropic drugs use -
- Gender
Both
- Mininum Age
55 Years
- Maximum Age
95 Years
- Healthy Volunteers
Accepts Healthy Volunteers
Resources
Source: Rambam Health Care Campus
Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
Locations
-
Neurocognitive unit,Neurophysiology laborator Rambam Health Care Campus
Haifa
31096
Israel
Officials
Judith Aharon-Peretz (Study Director, Rambam Health Care Campus)
Sponsors
Rambam Health Care Campus (Lead Sponsor)
None (Collaborator)
References
None.
Links
None.
- Date Verified
- September 1st, 2005
- First Received
- September 13th, 2005
- Last Changed
- September 13th, 2005
Information obtained from ClinicalTrials.gov on July 15, 2008. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.